European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research



Ferran, Jean-Marc and Nevitt, Sarah J ORCID: 0000-0001-9988-2709
(2019) European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research. BMC MEDICAL RESEARCH METHODOLOGY, 19 (1). 204-.

[img] Text
European Medicines Agency Policy 0070 an exploratory review of data utility in clinical study reports for academic research.pdf - Published version

Download (780kB) | Preview

Abstract

<h4>Background</h4>Clinical study reports (CSRs) have been increasingly utilised within academic research in recent years. European Medicines Agency (EMA) Policy 0070 'Phase 1,' which came into effect in January 2015, requires the publication of regulatory documents such as CSRs from central applications in an anonymised format. EMA Policy 0070 requires sponsors to demonstrate careful consideration of data utility within anonymised CSRs published within the scope of the policy, yet the concept of data utility is not clearly defined in the associated anonymisation guidance.<h4>Objective</h4>To review the use of data from CSRs in published academic research and to hypothesise the potential data utility of CSRs anonymised under the objectives of EMA Policy 0070 for future academic research.<h4>Methods</h4>Review of the objectives, research methodologies and findings of academic research reports using unpublished data from CSRs (prior to EMA Policy 0070). Semi-structured interviews with authors of academic research reports, including questions related to data utility of anonymised CSRs published under EMA Policy 0070.<h4>Results</h4>Thirteen academic research reports were identified and reviewed. The research purposes ranged from assessment of reporting bias, comparison of methods and results with published data sources, detailed evaluation of harms and adverse events, re-analysis and novel analyses including systematic reviews and meta-analysis. All of the examples identified required access to the methods and results sections of CSRs (including aggregated summary tables) and research purposes relating to evaluation of adverse events also required access to participant narratives. Retaining anonymised participant narratives relating to interventions, findings and events, while maintaining an acceptably low risk of participant re-identification, may provide an important gain in data utility and further understanding of drug safety profiles.<h4>Conclusions</h4>This work provides an initial insight into the previous use of CSR data and current practices for including regulatory data in academic research. This work also provides early guidance to qualitatively assess and document data utility within anonymised CSRs published under EMA Policy 0070.

Item Type: Article
Uncontrolled Keywords: Policy 0070, Regulatory, Anonymised, Clinical study reports, Data utility, Review
Depositing User: Symplectic Admin
Date Deposited: 18 Nov 2019 08:52
Last Modified: 20 Jan 2024 00:23
DOI: 10.1186/s12874-019-0836-3
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3062311